Amgen's multiple myeloma drug falls short in late stage study

(Reuters) - Amgen Inc said on Tuesday its cancer drug Kyprolis failed to meet the main goal of a late-stage study against Takeda Pharmaceutical Co Ltd's Velcade for treating newly diagnosed multiple myeloma.